# Study of TAK-925 in Participants With Obstructive Sleep Apnea (OSA) Who Are Experiencing Excessive Daytime Sleepiness (EDS) Despite Adequate Use of Continuous Positive Airway Pressure (CPAP)

> **NCT04091425** · PHASE1 · COMPLETED · sponsor: **Millennium Pharmaceuticals, Inc.** · enrollment: 25 (actual)

## Conditions studied

- Obstructive Sleep Apnea

## Interventions

- **DRUG:** TAK-925
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04091425
- **Lead sponsor:** Millennium Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-11-21
- **Primary completion:** 2020-04-02
- **Final completion:** 2020-04-02
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2020-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04091425

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04091425, "Study of TAK-925 in Participants With Obstructive Sleep Apnea (OSA) Who Are Experiencing Excessive Daytime Sleepiness (EDS) Despite Adequate Use of Continuous Positive Airway Pressure (CPAP)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04091425. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*